$ELUT Cashflow Statement | Understand Stock

$ELUT

$0.80 +$0.01 (0.85%) Close

$ELUT Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Gain on sale of Business
Loss on extinguishment of debt and revaluation of warrant liability
Loss on early repayment of debt
Amortization of deferred financing costs
(Gain) loss on revaluation of warrant liability
Gain on revaluation of revenue interest obligation
Amortization of deferred financing costs and debt discount
Interest expense recorded as additional revenue interest obligation or long-term debt
Stock-based compensation
Bad debt expense
Losses associated with viable bone matrix recall and market withdrawal
Other
Changes in operating assets and liabilities:
Payments on revenue interest obligation
Accounts receivable
Inventory
Receivables of litigation costs
Prepaid expenses and other
Accounts payable and accrued expenses and payables to tissue suppliers
Accounts payable and accrued expenses
Obligations to tissue suppliers
Contingent liability for FiberCel litigation
Deferred revenue and other liabilities
Contingent liability for legal proceedings
Other liabilities

Net cash used in operating activities
INVESTING ACTIVITIES:
Proceeds from sale of Business
Expenditures for property and equipment
Net cash used in investing activities
FINANCING ACTIVITIES:
Proceeds from public offering or private placement with warrants, net of offering costs
Repayments under revolving line of credit
Proceeds from stock option exercises
Proceeds from long-term debt
Proceeds (repayments) of long-term debt, net
Proceeds from exercises of Common Warrants and Prefunded Warrants
Payments on revenue interest obligation
Proceeds from insurance premium financings
Repayments of insurance premium financings
Payments for taxes upon vesting of restricted stock units
Proceeds from stock option exercises and issuance common stock under ESPP
Deferred financing costs
Repayments of long-term debt
Costs related to the extinguishment of debt
Net cash provided by financing activities

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental Cash Flow and Non-Cash Financing Activities Disclosures:
Cash paid for interest
Forgiveness of SBA PPP loan
Fair value of warrants issued
Operating lease right-of-use asset extensions executed, net of early terminations
Deferred proceeds from sale of CIED Business recognized as receivable
Issuance of common stock as payment under revenue interest obligation
Additions to operating lease right-of-use assets
Conversion of Common Warrants and Prefunded Warrants to common stock

Comments